Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-000788-42 | EudraCT Number |
Not provided
Not provided
target number of inclusion not reached
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pneumonia is the second common infection and its risk increases for elderly. In this population, it is the first cause of mortality by infections, and source of many complications. Geriatric studies had shown the high prevalence of ascorbic acid 's deficiency, especially in older hospitalized people. It is well known that vitamin C is one of the key of the immune system, it has a scavenger's role in case of aggression like sepsis. A Cochrane database published in 2013 analyzed the impact of vitamin C for preventing and treating pneumonia. Two randomized studies showed a benefit on respiratory symptoms for patients treated by vitamin C, and for one of those studies it was noted a significant reduction of mortality. The main objective of our study is first to determine the impact on respiratory symptoms of an adjuvant treatment by vitamin C for the management of pneumonia in older people hospitalized, and then evaluate its impact on functional status.
This study is French non-comparative phase II clinical trial, double-blind randomized, with placebo, single-center. One group would be treated the placebo group, and another would receive an adjuvant treatment by vitamin C : 500 mg twice a day by intra-venous way from the first day to the second included, and then 500 mg twice a day by oral way from the third day to the seventh. For each patient, the study's duration is 7 days, which is the mean stay of hospitalization. During those 7 days, we will make clinical exams and blood tests at d0, d2, d4 and d7. The vitamin C blood level will be measured at d0 and d7.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vitamin C | Experimental | Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime. |
|
| Placebo | Placebo Comparator | Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitamin C | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in the NYHA score between d-15 and d4 after treatment initiation | The NYHA score d-15 would be noted by medical staff at the inclusion by calling the patient's general practitioner. The NYHA score at d4 will be noted by investigators treating the patient. | 4 days after randomisation/treatment initiation |
| Measure | Description | Time Frame |
|---|---|---|
| The NYHA score at d2 and d7 | 2 and 7 days after randomisation/treament initiation | |
| Dyspnea's visual analogic scale at d2, d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation | |
Not provided
Inclusion Criteria:
people aged ≥ 75 years old
pneumonia's symptoms according to the SPILF (Société de Pathologie Infectieuse de Langue Française) :
pneumonia's symptoms developed between the admission's date in the unit care and the seventh day included
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aurélie LAFARGUE, MD | University Hospital Bordeaux (France) | Principal Investigator |
| Antoine BENARD, MD | University Hospital Bordeaux (France) | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux, Hôpital Saint André | Bordeaux | 33000 | France |
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001205 | Ascorbic Acid |
| ID | Term |
|---|---|
| D013400 | Sugar Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Blood saturation without oxygen therapy at d2, d4 and d7 |
| 2, 4 and 7 days after randomisation/treament initiation |
| Katz's ADL (Activities Daily Living) score at d2,d4 and d7 | Katz's ADL will be calculated by medical trained students or doctors at d2, d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation |
| Asthenia's evaluation at d2,d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation |
| Possibility for the patient to make his or her own transfer at d2,d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation |
| Morbidity-mortality at d2,d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation |
| Blood inflammation parameters at d2,d4 and d7 | Leukocytes and polynuclear neutrophil 's rates, with C-reactive protein will be measured at d2, d4 and d7 | 2, 4 and 7 days after randomisation/treament initiation |
| Vitamin C blood level at d7 | 7 days after randomisation/treament initiation |
| D006880 |
| Hydroxy Acids |
| D002241 | Carbohydrates |